Document:

<PAGE>

EXHIBIT 10.1

                        EXCLUSIVE DISTRIBUTION AGREEMENT

     THIS EXCLUSIVE DISTRIBUTION AGREEMENT (this "Agreement") is made and
entered into effective as of October 1, 2006 (the "Effective Date") by and
between Novare Surgical Systems, Inc., a corporation organized under the laws of
Delaware ("Novare"), with an address at 10440 Bubb Road, Suite A, Cupertino,
California 95014, and ATS Medical, Inc., a Minnesota corporation ("ATS"), with
an address at 3905 Annapolis Lane, Minneapolis, Minnesota 55447.

                                    RECITALS

A.   Novare is the owner of the Enclose II Anastomotic Assist Device and is
     engaged in, among other things, the manufacture, marketing, sale and
     distribution of the Enclose II Anastomotic Assist Device, and all
     accessories relating thereto, all as more fully described in Exhibit A
     hereto (collectively, the "Product").

B.   ATS has knowledge and capability to promote the sale of, and effectively
     distribute, the Product in the United States, Germany, France, and the
     United Kingdom, including all dependencies and territories of the foregoing
     (collectively, the "Territory").

C.   ATS desires to obtain from Novare, and Novare desires to grant to ATS, the
     exclusive right to market, sell and distribute the Product in the Territory
     on the terms and conditions set forth in this Agreement.

                                    AGREEMENT

     NOW, THEREFORE, in consideration of the foregoing recitals and the mutual
representations, warranties, covenants and agreements contained herein, the
Parties hereto agree as follows:

                                   ARTICLE I.
                                   DEFINITIONS

1.1  Act shall mean the U.S. Food, Drug and Cosmetic Act and the regulations
     promulgated thereunder, as amended from time to time.

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

<PAGE>

1.2  Affiliates shall mean, with respect to either party, those entities
     controlled by, in control of, or under common control with such party. For
     the purposes of this definition, "control" means ownership or control,
     direct or indirect, of more than fifty percent (50%) of the voting capital
     or equity participation of an entity.

1.3  ATS Confidential Information shall mean any non-public information, or
     scientific or technical data, know-how, or expertise of ATS, regardless of
     the form in which it is disclosed, existing as of the Effective Date or
     developed during the term of this Agreement. ATS Confidential Information
     includes, but is not limited to, any non-public information of ATS that
     relates in any way to the Products, its financial statements, marketing or
     finances, market research, customers, markets, product plans, business
     plans, services, software, developments, inventions, processes, procedures,
     methods, know-how, designs, data, programs, drawings, engineering
     information, organization, employees, agents, distributors or business in
     general of ATS or its Affiliates.

1.4  Initial minimum shall mean the product obtained **. Novare will provide ATS
     with Novare's documentation and records evidencing the relevant Product
     sales.

1.5  Novare Confidential Information shall mean any non-public information, or
     scientific or technical data, know-how, or expertise of Novare, regardless
     of the form in which it is disclosed, existing as of the Effective Date or
     developed during the term of this Agreement. Novare Confidential
     Information includes, but is not limited to, any non-public information of
     Novare that relates in any way to the Products, its financial statements,
     marketing or finances, market research, customers, markets, product plans,
     business plans, services, software, developments, inventions, processes,
     procedures, methods, know-how, designs, data, programs, drawings,
     engineering information, organization, employees, agents, distributors or
     business in general of Novare or its Affiliates.

1.6  Change in Control shall mean (i) any consolidation or merger of either
     party with or into any other corporation or other entity or person, or any
     other corporate reorganization, in which the stockholders of such party
     immediately prior to such consolidation, merger or reorganization, own less
     than fifty percent (50%) of such party's voting power immediately after
     such consolidation, merger or reorganization, or any transaction or series
     of related transactions to which either is a party in which in excess of
     fifty percent (50%) of such party's voting power is transferred or
     diminished; or (ii) a sale, lease or other disposition of all or
     substantially all the assets of either party; provided however that a
     "Change of Control" shall not include a Financing Transaction unless as a
     result of such Financing Transaction a Strategic Investor owns more than
     50% of the outstanding capital stock of the Company following the
     consummation of such Financing Transaction; and provided, further, however,
     that a "Change of Control" shall not result

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                        2

<PAGE>

     from the exercise of stock options granted by Novare to employees or
     consultants (who are not Strategic Investors) of the Company. A "Financing
     Transaction" shall mean the Company's sale of its capital stock other than
     as a result of the exercise of options or warrants, and a "Strategic
     Investor" shall mean an entity for which making equity investments is not
     one of the principal activities of such entity.

1.7  FDA shall mean the Food and Drug Administration of the U.S. Department of
     Health and Human Services.

1.8  GMP/QSR Regulations shall mean the applicable Good Manufacturing
     Practices/Quality System Regulations set forth under the Act.

1.9  Intellectual Property shall mean any U.S. or foreign patents and patent
     applications (including any substitutions, extensions, reissues, renewals,
     divisionals or continuations); trademarks, service marks and registrations
     thereof and applications therefore; copyrights and copyright registrations
     and applications; mask works and registrations thereof; all discoveries,
     innovations, ideas, inventions, technology, techniques, methods, know-how,
     trade secrets, processes, formulas, specifications, drawings and designs,
     computer programs or software, including all amendments, modifications and
     improvements to any of the foregoing, and any other proprietary
     information.

1.10 Transfer Price shall have the meaning ascribed thereto in Section 4.1.

                                   ARTICLE II.
                      APPOINTMENT AS EXCLUSIVE DISTRIBUTOR

2.1  Scope. Subject to ATS's compliance with all of the terms and conditions of
     this Agreement, Novare grants to ATS and its Affiliates the exclusive right
     to market, sell and distribute the Products in (and only in) the Territory
     during the term of this Agreement.

2.2  Exclusivity. ATS' distribution rights under this Agreement shall be
     exclusive in the Territory for the Products. Novare represents and warrants
     to ATS that subject to applicable law, as of the Effective Date, Novare is
     not party to any other agreements, written or oral, with any third party
     permitting the sale or distribution of Products in the Territory, and
     Novare covenants and agrees that from and after the Effective Date until
     the date this agreement terminates, Novare will not enter into any such
     agreement. In addition, from the Effective Date until the date this
     Agreement terminates, neither Novare nor its Affiliates will (i) engage in
     any sales, marketing or distribution of the Products in the Territory, or
     (ii) act as an agent or distributor in the sale of products that compete
     with any products of ATS or the Products covered under this Agreement in
     the Territory.

2.3  Additions to the Territory. Upon termination or change of existing
     distributors in countries outside of the Territory, Novare will give ATS 30
     days notice to agree to add

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                        3

<PAGE>

     such countries to the Territory by letter amendment to this agreement,
     including adjustment of the Minimum Purchase Requirements.

2.4  Subdistributors and Subagents. ATS may appoint subdistributors or subagents
     for distribution of the Products in the Territory. Notwithstanding such
     appointment of subdistributors or subagents, ATS shall remain fully
     responsible for the performance, acts and omissions of all of its and its
     Affiliates, subdistributors and subagents covenants, representations,
     warranties and obligations hereunder, and any sales by Novare to such
     subdistributor shall be billed by Novare to ATS directly.

2.5  Limitation of Rights. No rights or licenses are granted except as expressly
     and unambiguously set forth in this Agreement. Without limiting the
     foregoing, ATS acknowledges and agrees that it has no right to market or
     exploit the Products in any manner outside the Territory.

                                  ARTICLE III.
                         SUPPLY AND ORDERS FOR PRODUCTS

3.1  Purchase Orders. ATS shall submit purchase orders to Novare for the
     Products in writing or by facsimile or e-mail, which purchase orders shall
     include the following and no terms inconsistent with this Agreement: (a)
     identification of the Products ordered; (b) quantity; (c) requested
     delivery date; and (d) shipping instructions and shipping address. ATS
     shall ensure that its purchase orders are received by Novare at least six
     (6) weeks prior to the delivery dates requested in the purchase order.
     Novare will ship Products within six (6) weeks of receiving a purchase
     order. On a monthly basis during the term of this Agreement, ATS will
     provide Novare with a twelve (12)-month rolling forecast that defines for
     each calendar month during the rolling forecast number of units
     forecasted[, provided that no forecast for any particular month shall vary
     by more than 25% from the immediately preceding forecast for such month.

3.2  Acceptance of Orders. All purchase orders issued in accordance with this
     Agreement shall be automatically accepted by Novare. Each purchase order
     shall be deemed to be an irrevocable offer by ATS to purchase the
     quantities of Products specified pursuant to the terms of this Agreement
     and shall give rise to a contract between ATS and Novare for the sale of
     such Products ordered according to the terms specified therein subject to
     the terms of this Agreement. The terms and conditions of this Agreement
     shall govern and supersede any additional or contrary terms set forth in
     ATS' purchase order or any Novare or ATS acceptance, confirmation, invoice
     or other document, unless the specific additional or contrary terms are
     stated in writing and duly signed by an officer of ATS and an officer of
     Novare.

3.3  Modification of Orders. No purchase order shall be modified or canceled
     except upon the mutual written agreement of the parties, which shall not be
     unreasonably withheld by

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                        4

<PAGE>

     either party. Mutually agreed change orders shall be subject to all
     provisions of this Agreement, whether or not the changed purchase order so
     states. Notwithstanding the foregoing, any purchase order may be canceled
     by ATS as to any Products which are not delivered within thirty (30) days
     of the delivery date requested by ATS pursuant to a purchase order
     submitted to Novare under Section 4.1 and accepted by Novare under Section
     4.2 (the "Requested Delivery Date"), and any such cancellation shall not
     limit or affect any contract remedies available to ATS with respect
     thereto. Any such cancellation by ATS must be by written notice to Novare
     given within forty-five (45) days following the Requested Delivery Date and
     shall be effective as of the 30th day following the Requested Delivery
     Date.

3.4  Shipment. All Products sold by Novare to ATS shall be tendered for shipment
     by Novare free on board ("F.O.B.") Novare's designated manufacturing point
     (the "Shipping Point"). Novare shall bear all risk of loss prior to
     Novare's delivery of the Products to a common carrier at the Shipping
     Point, and shall have no further responsibility for the Products after it
     has delivered the Products to the common carrier. ATS assumes all risk of
     loss upon Novare's delivery of the Products to a common carrier at the
     Shipping Point. ATS shall pay all loading, freight, shipping, insurance,
     forwarding and handling charges, taxes, fees, storage, and all other
     charges applicable to the Products after they are delivered by Novare to
     the common carrier at the Shipping Point. If ATS requests any expedited
     shipping due to a modification of its purchase order pursuant to Section
     4.3, ATS shall be responsible for all such expedited shipping costs.

3.5  Inspection.

     (a)  Novare shall inspect all Products sold by Novare to ATS prior to
          shipment to ATS to validate that all such Products sold to ATS meet
          all of the then applicable specifications for such final Products.
          Novare shall include with the shipment of such Products a written
          proof of inspection for each Product shipped to ATS, which will
          provide such detail as requested by ATS.

     (b)  ATS shall conduct any incoming inspection tests on the Products within
          thirty (30) days of delivery of the Products to the Shipping Point,
          unless otherwise agreed by Novare. In cases where obligations of ATS
          to the customer do not allow for the completion of incoming inspection
          within this time, ATS shall notify Novare with the specific inspection
          terms at the time of submission of the purchase order, and shall also
          give notification to Novare when the inspection is completed. In the
          event of any shortage or damage (i.e. a failure of a Product to
          conform to Novare's specifications therefore) in or to a shipment of
          Products, ATS shall promptly give notice thereof to Novare and shall
          furnish such written evidence or other documentation as Novare
          reasonably may deem appropriate. If such evidence indicates that such
          shortage, damage or discrepancy existed at the time of delivery of the
          Products to the carrier, Novare will promptly deliver

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                        5

<PAGE>

          additional or replacement Products to ATS, without additional cost to
          ATS. Any Products not properly rejected by ATS by written notice given
          to Novare within such inspection period, shall be deemed to have been
          accepted. Following any such acceptance, the sole remedies of ATS with
          respect to damage to or defects in the Products shall be those set
          forth in Article 10 below.

     (c)  Any claims for shipping damage shall be submitted to Novare in
          accordance with the provisions of Section 3.5(b) above.

3.6  Testing. Novare shall be responsible for testing the Products to ensure
     that the product and sterilization testing and validation activities
     outlined in Exhibit B attached hereto meet the testing and validation
     activities ATS requires for its own products. Novare shall provide to ATS
     documented test results that demonstrate compliance with the activities
     outlined in Exhibit B.

3.7  Packaging, Sterilization and Labeling. Novare shall be responsible for
     finished goods, packaging, labeling, instructions for use, and any
     necessary and sterilization of Products purchased under this Agreement. If
     ATS desires or if a change in packaging, labeling or instructions for use
     is required in the Territory, Novare shall, at ATS's expense, deliver the
     text of proposed packaging, labeling, instructions for use to ATS for its
     review and comment prior to printing. ATS shall have thirty (30) days to
     review and provide comments on such packaging, labeling, instructions for
     use. Novare shall prepare packaging, labeling and instructions for use in
     English, German, French, ___ at ATS's sole cost and expense. The Products
     will be labeled as "Manufacturer: Novare" and either "ATS: ATS" or "ATS:
     ATS Medical, Inc." ATS hereby grants Novare a limited, non-exclusive,
     license to use ATS' name in accordance with ATS' instructions, solely for
     purposes of packaging and labeling Products sold by Novare to ATS or its
     Affiliates under this Agreement.

3.8  Subcontracts and Suppliers. If ATS requires information on the Products
     (for regulatory or operational purposes), Novare will promptly supply ATS a
     list of Novare's subcontractors and suppliers contributing to the
     manufacture of the Product. After Novare has supplied ATS with such list,
     Novare shall provide ATS with at least thirty (30)-days' notice of any
     proposed change in such subcontractors and suppliers.

3.9  Changes to Facility, Processing, Product Specifications and Material
     Specifications. Novare will inform ATS in writing at least thirty (30) days
     in advance of making any changes involving or effecting the Products, which
     changes are reportable to the FDA or which effect the safety or
     effectiveness of the Products, including, without limitation, the process
     which is used to manufacture the Products or the specifications for such
     Products or materials used in such Products.

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                        6

<PAGE>

                                   ARTICLE IV.
                               PRICES AND PAYMENTS

4.1  Transfer Prices. During the period from the Effective Date until December
     31, 2007 (the "Initial Price Period"), the transfer price for one box of
     the Product (each box will contain **) shall be ** (as such price may be
     adjusted from time to time, the "Transfer Price"). From time to time
     following the Initial Price Period, Novare may increase the Transfer Price
     after thirty (30) days notice to ATS and to the extent that Novare can
     demonstrate to ATS' reasonable satisfaction that **; provided, however,
     that no such increases shall, during any given calendar year, amount to an
     increase in more than ** over the Transfer Price in effect on December 31
     of the previous calendar year. All Transfer Prices are F.O.B. Shipping
     Point.

4.2  Payment Terms. Novare will invoice ATS upon delivery of Products to the
     Shipping Point. Invoices for Products shipped to ATS shall be due and
     payable in full within forty-five (45) days from the delivery of the
     applicable Products to the Shipping Point; provided, however, that payment
     for the first eighty (80) boxes received by ATS shall be due and payable in
     full within one hundred eighty (180) days after the delivery of such
     Products at the Shipping Point. All payments hereunder shall be made in
     U.S. dollars in the United States in immediately available funds.

4.3  Taxes. The Transfer Prices for Products do not include any sales, use,
     value added or similar taxes, customs duties, or tariffs imposed by any
     governmental authority or agency on Products or any components thereof that
     are imposed by ATS into any country in the Territory. ATS shall pay or
     reimburse Novare for all such amounts incurred in connection with ATS'
     purchase of Products; provided, however, that Novare shall pay all net
     income or franchise taxes imposed upon Novare.

4.4  Resale Prices. ATS may resell the Products at such prices as ATS, in its
     sole discretion, shall determine.

                                   ARTICLE V.
                           MINIMUM OBLIGATIONS OF ATS

5.1  Minimum Purchase Requirements. From the Effective Date until December 31,
     2006, ATS shall not have any minimum purchase requirement. For calendar
     year 2007, and subject to Section 5.2, ATS agrees to purchase and take
     delivery of at least that number of Products equal to the Minimum Units.
     During each calendar year after 2007, and subject to Section 5.2, ATS
     agrees to purchase and take delivery of at least that number of Products
     equal to the product obtained ** (as such number may have been adjusted in
     accordance with Section 5.2) (each such amount, a "Yearly Quota" and,
     collectively, the "Quota").

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                        7

<PAGE>

5.2  Reductions in Quota. Notwithstanding Section 5.1, the Yearly Quota for any
     calendar year shall be reduced by a pro rata amount of the Yearly Quota for
     the applicable calendar year based upon the number of days of such period
     which have transpired prior to the removal of the restriction on sale
     referenced in such subpart:

     (a)  If a Product covered by this Agreement is recalled from the United
          States of America market or withdrawn from sale for reasons of product
          safety or quality as determined by any applicable governmental
          authority in the United States of America or by the mutual agreement
          of the parties; or

     (b)  If ATS is restricted in the sale of Products in the United States of
          America by any applicable regulatory authority because approval to
          sell the Product is pending, denied or revoked or because the Products
          infringe any third party intellectual property rights.

     (c)  If ATS is restricted in the sale of Products in a market by any
          applicable regulatory authority because approval to sell the Product
          is pending, denied or revoked or because the Products infringe any
          third party intellectual property rights.

                                   ARTICLE VI.
                      GENERAL RIGHTS AND OBLIGATIONS OF ATS

6.1  Sales and Marketing. ATS will provide a level of sales and marketing
     support for the Products that is comparable to the sales and marketing
     support that ATS provides for any of its other products and will use
     commercially reasonable efforts on a continuous basis to further the
     promotion, marketing, sale and other distribution of the Products in the
     Territory. ATS will incorporate into its sales force compensation structure
     for the Products similar sales incentive arrangements as ATS has used for
     other products and, in particular, there will be a set commission rate for
     each representative based on the total amount of commissions expected at
     100% of plan divided by the sales revenue plan number. Additionally, total
     over-achievement bonus will increase commensurately as the sales
     representative achieves additional individual sales goals for our various
     product groups.

6.2  Training. ATS shall provide its sales force with all reasonably necessary
     and appropriate training and support regarding the use of the Products.
     Novare shall provide reasonable personnel and assistance in the training of
     ATS' sales force. Each party will be responsible for their own expenses
     incurred in connection with such training.

6.3  Alteration of Products. ATS shall not, in any way, alter the Products or
     remove, cover, change, alter or add to the labels attached to the Products
     by Novare, except with

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                        8

<PAGE>

     Novare's express prior written approval. In the event that Novare makes any
     changes or alterations to the Products, Novare shall not ship any such
     changed or altered Products to ATS unless Novare has notified ATS of such
     changes or alterations to the Products at least thirty (30) days before
     shipping any such altered or changed Products to ATS.

6.4  Import Approvals. ATS shall be responsible for obtaining all import
     licenses and permits (other than regulatory approvals under Article 11) as
     may be required to import the Products into any of the Territories in
     accordance with then prevailing laws and regulations of such Territory. All
     such filings and registrations of the Products shall be in the name of ATS,
     whenever feasible in accordance with prevailing laws and regulations.
     Novare shall cooperate reasonably with ATS in its efforts to obtain any
     such approvals.

6.5  Export. ATS shall be responsible for obtaining all required export licenses
     and other authorizations and permits from the United States Government for
     the sale of the Products to ATS. Novare shall cooperate reasonably with ATS
     in its efforts to obtain any such approvals.

6.6  Records and Recall. ATS shall, or shall cause its subdistributor to,
     maintain complete and accurate records of all Products sold by ATS and any
     subdistributors appointed pursuant to Section 2.3. In the event of a recall
     of any of the Products, ATS and any subdistributor will cooperate
     reasonably with Novare in effecting such recall.

6.7  Compliance with Laws. ATS shall at all times: (i) conduct its activities
     under this Agreement in strict compliance with all applicable laws, rules,
     regulations and governmental orders now or hereafter in effect in the
     Territory; (ii) pay any and all fees and other charges required by such
     laws, rules, regulations and orders; and (iii) have and maintain in full
     force and effect any and all licenses, permits, authorizations,
     registrations and qualifications from all governmental agencies, within or
     outside the Territory, to the extent necessary or appropriate to perform
     its obligations hereunder.

                                  ARTICLE VII.
                    GENERAL RIGHTS AND OBLIGATIONS OF NOVARE

7.1  Manufacture of Products. During the term of this Agreement, Novare shall
     manufacture and sell Products to ATS in accordance with the terms and
     conditions set forth in this Agreement, provided that if Novare fails to
     manufacture the Products or is unable meet the volume requirements set
     forth in any purchase order delivered by ATS under this Agreement, Novare
     shall promptly notify ATS in writing of such manufacturing deficiency. In
     addition, if ATS becomes aware of any such manufacturing deficiency, ATS
     shall provide written notice to Novare of such manufacturing deficiency. If
     Novare is not able to cure the deficiency within ninety (90) days of notice
     from ATS, ATS will have the right to terminate this Agreement.

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                        9

<PAGE>

7.2  Samples and Technical Support. Novare shall provide, at no charge, to ATS
     reasonable quantities of samples of the Product and accessories (if Novare
     has such in its possession). Novare will provide, at no charge, to ATS
     reasonable technical support related to the Product via telephone, mail and
     email for up to six (6) months after the date of this Agreement.

7.3  Marketing Materials. Novare shall provide to ATS, to the extent Novare has
     such in its possession, reasonable quantities of sales and marketing
     materials to be used by ATS in the marketing and sale of the Products in
     the Territory, and ATS may use such materials and make such translation,
     adaptation and/or modification of Novare's sales and marketing materials,
     as deemed appropriate by ATS, to reflect local culture or business
     practices and languages and a professional photo shoot of both individual
     Product photos and photos of Product in use. As provided in Article 14,
     Novare grants ATS the right to use the Novare and Enclose II tradenames and
     brands (and all related brand names and tradenames and marks related
     thereto) that are deemed reasonably necessary by ATS to promote the sales
     and marketing of the Product.

7.4  Sales Leads. Novare shall promptly forward to ATS all leads for sales of
     Products in the Territory.

7.5  Notification of Malfunctions. Each party shall notify the other party
     within 24 hours after such party becomes aware of information that suggests
     that the Products (a) may have caused or contributed to a death or serious
     injury, or (b) have malfunctioned and would be likely to cause or
     contribute to a death or serious injury if the malfunction were to recur.

7.6  Investigation of Customer Complaints and Non-conformity. In the event that
     ATS receives from its customers or its subdistributor complaints for the
     Products, the parties to this Agreement shall use diligent efforts to
     investigate possible causes of such complaints within a reasonable period
     of time.

                                  ARTICLE VIII.
                              TERM AND TERMINATION

8.1  Term. Subject to Section 8.2, this Agreement shall take effect as of the
     Effective Date, and its initial term shall be the three-year period
     following the Effective Date (the "Initial Term"). Thereafter, this
     Agreement shall automatically renew for consecutive one-year terms (each a
     "Renewal Period"), unless and until either gives written notice of
     termination to the other party at least six months prior to the end of the
     Initial Term or a Renewal Period, as applicable.

8.2  Termination. Notwithstanding the provisions of Section 8.1, this Agreement
     may be terminated in accordance with the following provisions:

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                       10

<PAGE>

     (a)  Either party may terminate this Agreement at any time by giving notice
          in writing to the other party, which notice shall be effective upon
          dispatch, should the other party file a petition of any type as to its
          bankruptcy, be declared bankrupt, become insolvent, make an assignment
          for the benefit of creditors, go into liquidation or receivership.

     (b)  Either party may terminate this Agreement by giving notice in writing
          to the other party should an event of Force Majeure, as defined below,
          continue for more than six months.

     (c)  Either party may terminate this Agreement by giving notice in writing
          to the other party in the event the other party is in material breach
          of this Agreement and shall have failed to cure such breach within
          thirty (30) days of receipt of written notice thereof from the
          non-breaching party.

     (d)  ATS may terminate this Agreement by giving thirty (30) days notice in
          writing to Novare, which notice shall be effective upon dispatch,
          should ATS exercise its right of first offer option as provided in
          Section 15.1 or if there shall occur a Change in Control of Novare.

8.3  Rights and Obligations on Termination. In the event of termination of this
     Agreement for any reason, the parties shall have the following rights and
     obligations:

     (a)  Termination of this Agreement shall not release either party from the
          obligation to make payment of all amounts then or thereafter due and
          payable.

     (b)  The terminating party shall have the right, at its option, to cancel
          any or all purchase orders that provide for delivery after the
          effective date of termination.

     (c)  ATS shall be permitted to resell any inventory of Products on hand at
          the time of termination.

     (d)  Both parties agree to cooperate to provide a smooth transition of
          business back to Novare including ATS to provide all historic sales
          and customer information of the Product(s).

     (e)  ATS' and Novare's obligations pursuant to this Section 8.3 and
          Articles 9, 10, 11, 12, 13, 14, 15 (as provided in Section 8.2(d), 16
          and 18 shall survive termination of this Agreement. All other
          provisions of this Agreement shall terminate upon termination of this
          Agreement.

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                       11

<PAGE>

                                   ARTICLE IX.
                               PRODUCT WARRANTIES

9.1  Limited Warranty.

     (a)  Novare warrants to ATS that all Products sold to ATS under this
          Agreement will conform to Novare's written specifications therefore
          under normal use and will have a minimum of eighteen (18) months of
          sterilization dating.

     (b)  Novare will replace any Product that it reasonably determines was
          defective at the time of shipment to ATS or that is the subject of any
          breach of any warranty by Novare or refund the amounts paid to Novare
          for such Product.

     (c)  Prior to returning any defective Product, ATS shall notify Novare in
          writing of the specific defect and shall include the model and
          lot/serial number of such Products, as well as the number and date of
          the invoice therefore. Novare will pay for the costs of shipping from
          ATS' warehouse to Novare any Product that Novare determines was
          defective and Novare shall pay for the costs of shipping to ATS or the
          end user any replacement of a Product that Novare determines was
          defective.

     (d)  The above warranty shall not apply with respect to damage to any
          Product caused by misuse, improper maintenance, improper storage,
          shipping, handling, alteration or repair by unauthorized personnel, or
          by neglect or accident.

9.2  Limited Warranty. THE WARRANTIES SET FORTH IN SECTION 9.1 ARE INTENDED
     SOLELY FOR THE BENEFIT OF ATS. ALL CLAIMS HEREUNDER SHALL BE MADE BY ATS
     AND MAY NOT BE MADE BY ATS' CUSTOMERS. THE WARRANTIES SET FORTH ABOVE ARE
     IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, WHICH ARE HEREBY
     DISCLAIMED AND EXCLUDED BY NOVARE AND ITS SUPPLIERS, INCLUDING WITHOUT
     LIMITATION ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
     PURPOSE OR USE AND NONINFRINGEMENT. THE SOLE AND EXCLUSIVE REMEDIES OF ATS
     FOR BREACH OF PRODUCT WARRANTY SHALL BE LIMITED TO THE REMEDIES PROVIDED IN
     THIS AGREEMENT.

9.3  Liability Limitation. IN NO EVENT SHALL NOVARE OR ITS SUPPLIER'S LIABILITY
     UNDER CONTRACT, TORT, STRICT LIABILITY OR ANY OTHER LEGAL THEORY FOR
     PRODUCT WARRANTY OR ANY OTHER SUBJECT MATTER OF THIS AGREEMENT INCLUDE ANY
     SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL LOSSES OR DAMAGES, EVEN IF
     NOVARE SHALL HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH POTENTIAL

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                       12

<PAGE>

     LOSS OR DAMAGE. THE FOREGOING LIMITATIONS SHALL NOT LIMIT NOVARE'S
     OBLIGATIONS PURSUANT TO SECTION 10.1.

                                   ARTICLE X.
          INDEMNIFICATION; INSURANCE AND REPRESENTATIONS AND WARRANTIES

10.1 Indemnification.

     (a)  Cross Indemnity. Novare and ATS hereby agree to indemnify, defend and
          hold each other harmless from and against all suits, actions, claims,
          demands, causes of action, judgments, liabilities and expenses
          (including court costs and reasonable attorney fees) (collectively,
          "Losses") which arise or result from their respective
          misrepresentations of any representation contained herein, or default
          in the observance or performance of any term or provision hereof.

     (b)  Indemnification by ATS. ATS shall indemnify, defend and hold Novare
          and its Affiliates (each a "Novare Indemnified Party") harmless from
          and against all suits, actions, claims, demands, causes of action,
          judgments, liabilities and expenses (including court costs and
          reasonable attorney fees) (collectively, "Losses") which are the
          result of ATS' relationship with a subdistributor of ATS or any other
          third parties appointed by ATS to distribute the Products or of ATS's
          gross negligence or willful misconduct.

     (c)  Indemnification by Novare. Novare shall indemnify, defend and hold ATS
          and its Affiliates (each an "ATS Indemnified Party") harmless from and
          against all Losses which arise out of or result from third party
          claims of personal injury arising from a breach of Section 9.1 or of
          Novare's gross negligence or willful misconduct. As a condition
          precedent to Novare's obligation under this Section 10.1(b), an ATS
          Indemnified Party charged in such suit shall promptly notify Novare,
          shall reasonably cooperate with Novare in the defense and any
          settlement thereof, and shall not settle any suit or claim for which
          it seeks indemnification hereunder without Novare's prior written
          approval and it shall give Novare the right to defend and control such
          actions at its sole expense.

10.2 Insurance Requirements.

     (a)  Novare Insurance Requirements. Novare will carry product liability
          insurance covering any loss, damage, expense or liability incurred or
          suffered by any party other than Novare arising out of any use of any
          of the Products. Such policy or policies shall (i) have aggregate
          limits of liability of not less than $500,000 with respect to any
          incident or occurrence and of not less than $2 million in the
          aggregate; (ii) name ATS as an additional insured party; (iii) provide
          for a deductible or retained amount of not more than $50,000 each
          occurrence and

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                       13

<PAGE>

          $250,000 in the aggregate; and (iv) provide that such policy may not
          be canceled except upon not less than thirty (30) days' written notice
          to both Novare and ATS. Upon request, Novare shall provide such
          evidence of the effectiveness of such insurance to ATS.

     (b)  ATS Insurance Requirements. ATS will carry product liability insurance
          covering any loss, damage, expense or liability incurred or suffered
          by a party other than ATS arising out of any use of any of the
          Products. Such policy or policies shall (a) have aggregate limits of
          liability of not less than US$10 million with respect to any incident
          or occurrence and of not less than US$25 million in the aggregate; (b)
          name Novare as an additional insured party; (c) provide for a
          deductible or retained amount of not more than US$50,000 each
          occurrence and US$250,000 in the aggregate; and (d) provide that such
          policy may not be canceled except upon not less than thirty (30) days'
          written notice to both Novare and ATS. Upon request, ATS shall provide
          evidence of the effectiveness of such insurance to Novare.

10.3 Third Party Claims. If a claim by a third party is made against an
     indemnified party and if the indemnified party intends to seek indemnity
     with respect thereto under this Article 10, such indemnified party shall
     promptly notify the indemnifying party of such claim; provided, however,
     that the failure to give timely notice shall not affect the rights of the
     indemnified party so long as such failure to give timely notice does not
     adversely affect the indemnifying party's ability to defend such claim
     against a third party. The indemnifying party shall be entitled to assume
     the defense thereof, with counsel selected by the indemnifying party and
     reasonably satisfactory to the indemnified party. The indemnifying party
     shall have control of the defense of any such action, including any appeals
     and negotiations for the settlement or compromise thereof and shall have
     full authority to enter into a binding settlement or compromise; provided
     that, the indemnifying party shall not enter into any settlement or
     compromise which may adversely affect the indemnified party without the
     indemnified party's consent, which consent shall not be unreasonably
     withheld. If the indemnifying party assumes the defense of such claim, the
     indemnifying party shall not be responsible for any legal or other expenses
     subsequently incurred by such indemnified party in connection with the
     defense thereof. The indemnified party may participate, at its own cost and
     expense, in the defense of any such claim; provided, however, that such
     defense shall be controlled by the indemnifying party.

10.4 Cooperation as to Indemnified Liability. Each party hereto shall cooperate
     reasonably with other parties with respect to access to books, records, or
     other documentation within such party's control, if deemed reasonably
     necessary or appropriate by any party in the defense of any claim, which
     may give rise to indemnification hereunder.

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                       14

<PAGE>

10.5 ATS' Representations and Warranties. ATS hereby represents and warrants to
     Novare that as of the Effective Date:

     (a)  ATS is a corporation duly organized, validly existing and in good
          standing under the laws of Minnesota, and this Agreement has been duly
          authorized by all necessary corporate action.

     (b)  This Agreement is the legal, valid and binding obligation of ATS,
          enforceable against ATS in accordance with its terms.

     (c)  Neither the execution and delivery of this Agreement nor the
          performance of any of its obligations hereunder conflicts with or
          constitutes a breach or violation by ATS or constitute a default under
          any obligation of ATS or under any material contract, agreement or
          other instrument to which ATS is a party or any other obligation by
          which ATS is bound.

     (d)  There is no legal, administrative, arbitration, or other proceeding,
          suit, claim or action of any nature, judgment, decree, decision,
          injunction, writ or order pending or, to the knowledge of ATS,
          threatened or contemplated by or against or involving ATS or its
          shareholders directors or officers (but only in their capacity as
          such), ATS Confidential Information or this Agreement, whether at law
          or in equity, before or by any person, entity governmental or
          quasi-governmental, administrative or regulatory agency or any court.

     (e)  ATS is not under any obligations inconsistent with the provisions of
          this Agreement.

10.6 Novare's Representations and Warranties. Novare hereby represents and
     warrants to ATS that as of the Effective Date:

     (a)  Novare is a corporation duly organized, validly existing and in good
          standing under the laws of Delaware, and is duly qualified to do
          business in California, and this Agreement has been duly authorized by
          all necessary corporate action.

     (b)  This Agreement is the legal, valid and binding obligation of Novare,
          enforceable against Novare in accordance with its terms.

     (c)  Neither the execution and delivery of this Agreement nor the
          performance of any of its obligations hereunder conflicts with or
          constitute a breach or violation by Novare or constitute a default
          under any obligation of Novare or under any material contract,
          agreement or other instrument to which Novare is a party or any other
          obligation by which Novare is bound.

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                       15

<PAGE>

     (d)  There is no legal, administrative, arbitration, or other proceeding,
          suit, claim or action of any nature, judgment, decree, decision,
          injunction, writ or order pending or, to the knowledge of Novare,
          threatened or contemplated by or against or involving Novare or its
          shareholders directors or officers (but only in their capacity as
          such), Novare Confidential Information or this Agreement, whether at
          law or in equity, before or by any person, entity governmental or
          quasi-governmental, administrative or regulatory agency or any court.

     (e)  Novare is not under any obligations inconsistent with the provisions
          of this Agreement.

                                   ARTICLE XI.
                             REGULATORY SUBMISSIONS

11.1 Medical Device Establishment Registration. Novare shall maintain a Medical
     Device Establishment Registration (as defined under the Act) as
     manufacturer and specifications developer for the Products, as is required.

11.2 U.S. Approval. Novare shall be responsible, at its expense, for filing and
     obtaining and maintaining all necessary authorizations from regulatory
     authorities of the U.S. federal government, including the FDA, or of the
     various states necessary for the sale of the Products in the United States.
     Novare's obligations under this Section 11.2 shall include the preparation
     and filing of any required submissions and the establishment and oversight
     of any required clinical investigations and clinical follow-up relating to
     future commercial sale of the Products.

11.3 Foreign Approvals. Subject to Section 11.2, Novare shall be responsible,
     and at [ATS] expense, for maintaining all existing "device" or "medical"
     regulatory approvals from foreign regulatory authorities necessary for the
     commercial sale of the Products ("Foreign Approvals") within the Territory
     in accordance with this Section 11.3. All new Foreign Approvals shall, to
     the extent permitted, be in ATS' name. Novare shall maintain the CE Mark.
     Novare's obligations under this Section 11.3 shall include, at ATS expense,
     assisting in the preparation and filing of any required submissions
     relating to future commercial sale of the Products to the extent required
     for marketing and sales of Products in the Territory. Except as otherwise
     required by law or agreed by the parties and at ATS expense, Novare shall
     be primarily responsible for all dealings with the appropriate Competent
     Authority within the Territory such as Notification, Medical Device
     Vigilance and national labeling issues, and Novare shall bear final legal
     responsibility for the content of all its own labeling.

11.4 Manufacturing Compliance. Novare represents and warrants to ATS that the
     Products sold under this Agreement will be manufactured, labeled, and
     packaged in accordance with all applicable international, federal, state
     and local laws and regulations the Act and

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                       16

<PAGE>

     GMP/QSR Regulations. Novare represents and warrants to ATS that Novare's
     manufacturing facilities, and the facilities of any OEM manufacturers or
     subcontractors, are in compliance with all GMP/QSR Regulations and ISO
     13485:2003 requirements and that Novare has the approvals and consents
     required to mark the Products with the "CE" mark.

11.5 Complaints and Medical Device Reporting. Each party will comply with
     applicable provisions of the Medical Device Reporting systems, including
     the requirements of 21 CFR Part 803, and each party will cooperate with the
     other for the efficient compliance therewith. ATS agrees to notify Novare
     within two (2) business days of receipt from any customer of any complaint
     or Medical Device Report ("MDR") filable complaint relating to the Product.
     ATS will investigate such complaint or MDRs/Vigilance Reports and forward
     to Novare all information relating to any defects in the performance,
     design, or quality of the Products. Novare shall investigate all instances
     of Product failure or inadequacy documented by ATS and forwarded by ATS for
     investigation. Novare shall provide a written summary of the findings from
     such investigation to ATS within seven (7) business days following the date
     that Novare is informed of such complaint or MDR. Novare shall have sole
     responsibility for filing the MDR with the appropriate regulatory agency.

11.6 Vigilance Reporting. ATS will notify Novare in writing if a Vigilance
     Report is required to be filed with respect to the Product. ATS, at its
     sole cost and expense, will be responsible for complying with Vigilance
     Reporting requirements for the Products in cooperation with Novare as the
     manufacturer of the Products. Novare will remain responsible for any and
     all Product investigations.

11.7 Regulatory Inspections. Novare will promptly notify ATS of any inspection
     of its facilities manufacturing the Product or any component part of a
     Product by the FDA, ISO, CE mark certification organization or other
     federal, state, or local regulatory agency which relates to the
     manufacture, assembly, or packaging of the Products and provide ATS with
     information about the progress and outcome of such inspection, including,
     without limitation, copies of any notice of observations or warnings,
     requests for remedial action, corrective actions or other adverse findings.

                                  ARTICLE XII.
                            CONFIDENTIAL INFORMATION

12.1 Confidentiality. Except as otherwise specifically provided in this
     Agreement, ATS and Novare each agree that during the term of this Agreement
     and thereafter, it will not use any Novare Confidential Information or ATS
     Confidential Information, respectively, for any purpose other than as
     permitted or required for performance by such party under this Agreement
     and not to disclose or provide any Confidential Information to any third
     party and to take all reasonably necessary measures to prevent any such
     disclosure by its

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                       17

<PAGE>

     employees, agents, contractors or consultants. Upon request of the other
     party or termination of this Agreement, each party shall return all such
     Confidential Information to the other party.

12.2 Existence of Agreement. The existence of this Agreement and the
     participation of the parties in it shall be deemed to be Confidential
     Information subject to the provisions of this Article 12 (and in particular
     subject to the disclosure obligations of the parties under applicable law
     and regulation). Any publication, public reference or other transfer of
     information into the public sector regarding the relationship as defined in
     the Agreement or any of the terms contained in the Agreement shall be
     prohibited without prior written consent of the other party; provided,
     however, that either party may make any public disclosure it believes in
     good faith is required by applicable law or any listing agreement
     concerning publicly-traded securities, in which case the disclosing party
     will use its reasonable efforts to advise the other Party prior to making
     the disclosure, and further provided, that if the non-disclosing party
     wishes to request that confidential treatment be obtained for any portion
     of this Agreement, then the parties will cooperate in good faith to seek to
     obtain such confidential treatment without any obligation to incur material
     expense. Without limiting the foregoing, the parties may each disclose this
     Agreement for diligence purposes in connection with financing and
     acquisition activities, provided that the disclosing party shall provide
     simultaneous written notice to the other party concerning the need for such
     disclosure.

12.3 Exclusions to Confidential Information. Confidential Information of either
     party shall exclude information that:

     (a)  was already in the possession of receiving party prior to its receipt
          from the disclosing party (provided that the receiving party is able
          to provide the disclosing party with reasonable documentary proof
          thereof);

     (b)  is or becomes part of the public domain by reason of acts not
          attributable to the receiving party;

     (c)  is or becomes available to receiving party from a source other than
          the disclosing party which source, to the best of receiving party's
          knowledge, has rightfully obtained such information and has no
          obligation of non-disclosure or confidentiality to the disclosing
          party with respect thereto;

     (d)  is made available by the disclosing party to a third party
          unaffiliated with the disclosing party on an unrestricted basis;

     (e)  is independently developed by the receiving party completely without
          reference to any Confidential Information of the disclosing party, as
          evidenced by the receiving party's written records; or

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                       18

<PAGE>

     (f)  has been or must be publicly disclosed by reason of legal, accounting
          or regulatory requirements beyond the reasonable control, and despite
          the reasonable efforts of the receiving party.

                                  ARTICLE XIII.
                    PATENTS AND INTELLECTUAL PROPERTY RIGHTS

13.1 Defense of Claims. Novare shall, at its own expense, defend any suit
     instituted against ATS which is based on an allegation that any Product
     constitutes an infringement of any patent or any other Intellectual
     Property right protected under the laws of the United States, any State of
     the United States, or any other nation. Novare shall have control of the
     defense of any such action, including any appeals and negotiations for the
     settlement or compromise thereof and shall have full authority to enter
     into a binding settlement or compromise; provided that, Novare shall not
     enter into any settlement or compromise which may adversely affect ATS
     without ATS' consent, which consent shall not be unreasonably withheld.
     Novare shall indemnify ATS against any award of damages and costs made
     against ATS as a result of any such action.

13.2 Limitation of Liability. Novare shall have no liability of any kind to ATS
     under Section 13.1 or based upon any other claim ATS may have to the extent
     any such claim is based upon or arises out of (a) the use of any Product in
     combination with an apparatus or device not manufactured, supplied or
     approved by Novare, (b) the use of any Product in a manner for which it was
     not designed or intended to be used, or (c) any modification of any Product
     by ATS or any third party which causes it to become infringing.

13.3 Replacement Product. In order to avoid or limit any liability for
     infringement, Novare may, at any time and irrespective of whether it shall
     be obligated to do so by order of any court, at its expense and option
     replace any Product with a non-infringing item providing substantially the
     same performance and has received all necessary regulatory approvals.

13.4 Intellectual Property. Novare represents and warrants to ATS that: (a)
     Novare owns or possesses licenses or other rights of which it has knowledge
     to use all Intellectual Property used in the development, manufacture or
     sale of the Products ("Novare Intellectual Property"); (b) no claim is
     pending or to Novare's knowledge threatened to the effect that the Product
     or Novare's use of Novare Intellectual Property infringes upon or conflicts
     with the valid rights of any other person under any Intellectual Property
     rights, and, to the best of Novare's knowledge, there is no basis for any
     such claim; and (c) no claim is pending or to its knowledge threatened to
     the effect that any such Novare Intellectual Property is invalid or
     unenforceable by Novare, and, to Novare's knowledge, there is no basis for
     any such claim (whether or not pending or threatened).

13.5 Protection of Novare's Intellectual Property and Improvements. Novare shall
     be responsible for filing and prosecuting all U.S. and foreign patent,
     copyright, trademark

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                       19

<PAGE>

     and mask work applications necessary or appropriate to protect Novare
     Intellectual Property in the Territory.

                                  ARTICLE XIV.
                                   TRADEMARKS

14.1 License. Novare hereby grants to ATS and its subdistributors a
     non-exclusive, non-transferable, and royalty-free right and license to use
     Novare's trademarks (including without limitation the name Enclose II or
     Novare), trade names and logotypes in connection with the sale,
     distribution, promotion and advertising of the Products as long as such
     trademarks are used by ATS in accordance with Novare's standards,
     specifications and instructions, but in no event beyond the term of this
     Agreement. ATS shall not acquire any right, title or interest under the
     laws of any nation in such trademarks, trade names or logotypes of Novare
     other than the foregoing limited license and shall not attempt to assert or
     register any such right, title or interest. ATS shall not use any of
     Novare's trademarks, trade names or logotypes as part of ATS' corporate or
     trade names or permit any third party to do so without the prior written
     consent of Novare. ATS shall in addition have the right to promote and sell
     the Products under trademarks, trade names and logotypes of ATS selected by
     ATS, which trademarks, trade names and logotypes shall be and shall remain
     the property of ATS.

14.2 Registration. Novare shall maintain all existing registrations of the
     trademarks referred to in Section 14.1 in such jurisdictions within the
     Territory. In addition, in the event ATS believes that it is advisable to
     effect any filing or obtain any governmental approval or sanction for the
     use by ATS of any trademarks of Novare pursuant to this Agreement, the
     parties will reasonably cooperate in order to do so. All expenses relating
     to new registration of such trademarks in the Territory, as well as the
     making of any filing or obtaining any governmental approval for the use by
     ATS of such trademarks, shall be borne by ATS.

14.3 Infringement. Novare reserves the right in its sole discretion to institute
     any proceedings against any third party using Novare's trademarks, trade
     names, logotypes or similar marks which may constitute an infringement or
     passing off of Novare's trademarks, trade names or logotypes, and ATS shall
     refrain from doing so. ATS agrees to cooperate fully with Novare in any
     action taken by Novare against such third parties, provided that all
     expenses of such action shall be borne by Novare and all damages which may
     be awarded or agreed upon in settlement of such action shall accrue to
     Novare.

14.4 Termination of Use. ATS acknowledges Novare's proprietary rights in and to
     Novare's trademarks, trade names and logotypes. Upon termination of this
     Agreement, ATS shall cease using Novare's trademarks, trade names and
     logotypes in any manner, subject to ATS' right, if any, to continue to sell
     Products under Section 8.3(c).

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                       20

<PAGE>

                                   ARTICLE XV.

     **

                                  ARTICLE XVI.
                                   ARBITRATION

16.1 Disputes. Any dispute, controversy or claim arising out of or relating to
     this Agreement, or the breach, termination or invalidity thereof, shall be
     finally settled by arbitration in accordance with the Commercial
     Arbitration Rules of JAMS in effect on the date of this Agreement by a
     single arbitrator who shall be experienced in the medical device industry
     and who shall be appointed in accordance with such rules. The place of
     arbitration shall be Wilmington, Delaware.

                                  ARTICLE XVII.
                                  FORCE MAJEURE

17.1 Definition. Force Majeure shall mean any event or condition, not existing
     as of Effective Date, not reasonably foreseeable as of such date and not
     reasonably within the control of either party, which prevents in whole or
     in material part the performance by one of the parties of its obligations
     hereunder or which renders the performance of such obligations so difficult
     or costly as to make such performance commercially unreasonable. Without
     limiting the foregoing, the following shall constitute events or conditions
     of Force Majeure: riots, civil or military disturbances, war, strikes,
     lockouts, labor slowdowns or stoppages, prolonged shortage of energy
     supplies, epidemics, fire, flood, hurricane, typhoon, earthquake,
     lightning, and explosion.

17.2 Notice. Upon giving notice to the other party, a party affected by an event
     of Force Majeure shall be released without any liability on its part from
     the performance of its obligations under this Agreement, except for the
     obligation to pay any amounts due and owing hereunder, but only to the
     extent and only for the period that its performance of such obligations is
     prevented by the event of Force Majeure. Such notice shall include a
     description of the nature of the event of Force Majeure, its cause and
     possible consequences. The party claiming Force Majeure shall promptly
     notify the other party of the termination of such event.

17.3 Suspension of Performance. During the period that the performance by one of
     the parties of its obligations under this Agreement has been suspended by
     reason of an event of Force Majeure, the other party may likewise suspend
     the performance of all or part of its obligations hereunder, except for the
     obligation to pay any amounts due and owing hereunder, to the extent that
     such suspension is commercially reasonable.

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                       21

<PAGE>

                                 ARTICLE XVIII.
                                 MISCELLANEOUS

18.1 Governing Law. This Agreement shall be governed by, and interpreted and
     construed in accordance with the laws of the State of Delaware, without
     giving effect to its conflict of laws principles or rules.

18.2 Relationship. This Agreement does not make either party the employee, agent
     or legal representative of the other for any purpose whatsoever. Neither
     party is granted any right or authority to assume or to create any
     obligation or responsibility, express or implied, on behalf of or in the
     name of the other party. In fulfilling its obligations pursuant to this
     Agreement each party shall be acting as an independent contractor.

18.3 Assignment. Except as otherwise provided in this Agreement, neither party
     may assign or otherwise transfer its rights and obligations under this
     Agreement without the prior written consent of the other party.
     Notwithstanding any other provision in this Agreement to the contrary, and
     subject to ATS' rights as set forth in Article 15, without the consent of
     the other party, either party may assign this Agreement to its successor in
     connection with a Change in Control of such party. Any prohibited
     assignment shall be null and void. All terms and conditions of this
     Agreement shall be binding on and inure to the benefit of the successors
     and permitted assigns of the parties.

18.4 Notices. Notice permitted or required to be given under this Agreement
     shall be deemed sufficient if given in writing by facsimile, commercial air
     delivery service or by registered or certified air mail, postage prepaid,
     return receipt requested, addressed to the respective addresses of the
     parties set forth below or at such other address as the respective parties
     may designate by like notice from time to time. Notices so given shall be
     effective upon the earlier of: (a) receipt by the party to which notice is
     given (which, in the instance of a facsimile, shall be deemed to have
     occurred at the time that the machine transmitting the facsimile verifies a
     successful transmission of the facsimile); (b) on the seventh business day
     following the date such notice was deposited in the mail; or (c) on the
     second business day following the date such notice was delivered to a
     commercial air delivery service. Notices shall be given as follows:

     If to Novare:     Novare Surgical Systems, Inc.
                       10440 Bubb Road, Suite A
                       Cupertino, California 95014

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                       22

<PAGE>

     If to ATS:        ATS Medical, Inc.
                       3905 Annapolis Lane North
                       Minneapolis, Minnesota 55447
                       Attn: Vice President, Marketing
                       and Business Development
                       Fax: (763) 553-1492

     With a copy to:   Oppenheimer Wolff & Donnelly LLP
                       3300 Plaza VII
                       45 South Seventh Street
                       Minneapolis, Minnesota 55402
                       Attn: Thomas A. Letscher
                       Fax: (612) 607-7100

18.5 Entire Agreement. This Agreement, including the exhibits and schedules
     attached hereto and incorporated as an integral part of this Agreement,
     constitutes the entire agreement of the parties with respect to the subject
     matter hereof, and supersedes all previous proposals, oral or written, and
     all negotiations, conversations or discussions heretofore had between the
     parties related to this Agreement.

18.6 Amendment. This Agreement shall not be deemed or construed to be modified,
     amended, rescinded, canceled or waived, in whole or in part, other than by
     written amendment signed by the parties hereto, except as expressly
     provided in this Agreement.

18.7 Severability. In the event that any of the terms of this Agreement are in
     conflict with any rule of law or statutory provision or otherwise
     unenforceable under the laws or regulations of any government or
     subdivision thereof, such terms shall be deemed stricken from this
     Agreement, but such invalidity or unenforceability shall not invalidate any
     of the other terms of this Agreement and this Agreement shall continue in
     force, unless the invalidity or unenforceability of any such provisions of
     this Agreement substantially violates, comprises an integral part of or is
     otherwise inseparable from the remainder of this Agreement.

18.8 Counterparts. This Agreement shall be executed in two or more counterparts,
     and each such counterpart shall be deemed an original hereof.

18.9 Waiver. No failure by either party to take any action or assert any right
     hereunder shall be deemed to be a waiver of such right in the event of the
     continuation or repetition of the circumstances giving rise to such right.

                  [Remainder of Page Intentionally Left Blank]

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                       23

<PAGE>

     IN WITNESS WHEREOF, the parties have caused this Agreement to be executed
on the date first above written.

                                      ATS MEDICAL, INC.

                                      By: /s/ Richard A. Curtis
                                          --------------------------------------
                                      Name: Richard A. Curtis
                                      Title: Vice President

                                      NOVARE SURGICAL SYSTEMS, INC.

                                      By: /s/ Kerry Pope
                                          --------------------------------------
                                      Name: Kerry Pope
                                      Title: Chief Executive Officer & President

**   The appearance of a double asterisk denotes confidential information that
     has been omitted from the exhibit and filed separately, accompanied by a
     confidential treatment request, with the Securities and Exchange Commission
     pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

                                       24
<PAGE>

                                    EXHIBIT A

                            PRODUCTS AND ACCESSORIES

<PAGE>

                                    EXHIBIT B

    Product and Sterilization Testing and Validation Activities (Section 3.7)<PAGE>

EXHIBIT 10.2

                            AMENDMENT NO. 2 TO LEASE

     THIS AMENDMENT NO. 2 TO LEASE ("Amendment") made as of September 1, 2006,
by and between ST. PAUL PROPERTIES, INC., a Delaware corporation ("Landlord")
and ATS MEDICAL, INC., a Minnesota corporation ("Tenant").

                                   WITNESSETH:

     WHEREAS, Landlord and Tenant are parties to that certain Lease dated April
29, 2000 (the "Original Lease"), for premises described therein (the
"Premises"); and

     WHEREAS, Landlord and Tenant entered into a certain Amendment No. 1 to
Lease dated May 1, 2001 (the "First Amendment"; the Original Lease and the First
Amendment are collectively, hereinafter the "Lease"); and

     WHEREAS, Landlord and Tenant wish to amend the Lease to reflect certain
additional agreements between them.

     NOW, THEREFORE, in consideration of the Premises and for good and valuable
consideration, the parties agree as set forth below.

     1. Defined Terms. Unless otherwise indicated, capitalized terms shall be
defined in the manner set forth in the Lease.

     2. Extension of Term. The Term of the Lease is hereby extended for a period
of twenty four (24) months commencing August 1, 2008 (the "Extension
Commencement Date") and ending on July 31, 2010 (such period the "Extension
Term").

     3. Base Rent. During the Extension Term, Tenant shall pay Base Rent for the
Premises in the amount of

          (a) $123,937.68 per annum, ($10,328.14 per month) for the period from
     the Extension Commencement Date through and including July 31, 2009; and

          (b) $126,416.40 per annum ($10,534.70 per month), for the period from
     August 1, 2009, through and including July 31, 2010,

without deduction or setoff therefrom, payable at the time and in the manner set
forth in the Lease for the payment of Base Rent.

     4. Amendment. Paragraphs 30 and 31 of the Lease are hereby deleted in their
entirety.

<PAGE>

     5. Additional Agreements.

          (a) HVAC Units. The parties agree that to the extent Landlord, in its
     sole discretion, determines that any or all of the HVAC units serving the
     Premises need replacement at any time on or after the Extension
     Commencement Date, Landlord shall do so, and the cost thereof shall be
     amortized over a twelve year period from the date of installation thereof,
     which amortization shall be based upon equal payments of principal and
     interest over said twelve year period, and interest shall be at the rate of
     nine percent (9%) per annum. Throughout that portion of the Term during
     which such amortization occurs, Tenant shall pay, as a part of Operating
     Costs, all of such amortization, including interest as specified above.

          (b) Cross Default. Any default by Tenant under that certain Lease
     December 22, 1987, between Helix BioCore, Inc. and Crow Plymouth Land
     Limited Partnership, as amended and assigned, for premises located at 3905
     Annapolis Lane, Plymouth, Minnesota, shall be a default under the Lease, as
     amended by this Amendment.

          (c) Condition of Premises. The Premises shall be taken by Tenant, as
     of the Extension Commencement Date in their then AS-IS, WHERE-IS, WITH ALL
     FAULTS condition.

          (d) Renewal of Lease. Landlord hereby grants to Tenant a one-time
     option to renew the Lease as to the Premises upon the terms and conditions
     of this Paragraph 5(d) if:

               (i) Tenant is not in default under this Lease, as the same may
          have been renewed beyond any time to cure at the time such option is
          exercised; and

               (ii) Tenant gives Landlord written notice of the exercise of the
          renewal of this Lease not later than nine months prior to the end of
          the term (the "Renewal Notice of Exercise"), time being of the
          essence. Tenant's failure to notify Landlord of its intent to exercise
          its option to renew the Term granted herein on or before the dates
          specified in this subparagraph (ii) for such renewal shall be deemed a
          waiver of Tenant's right to exercise its option to renew.

          If Tenant elects to renew this Lease under this Paragraph 5(d) the
     following terms and conditions shall apply:

               (i) The renewal term in question shall commence on August 1, 2010
          continue thereafter for a period of three (3) years.

               (ii) Base Rent for the Premises for the renewal term shall be
          Market Rent (as defined in Paragraph 5(e) of this Amendment); and

               (iii) All of the other terms and conditions contained in this
          Lease, as it may have been amended from time to time, shall be as set
          out in the Lease, it being understood that there shall be no rights of
          renewal or extension except as provided in

<PAGE>

          this Paragraph 5(d), and, upon the exercise of the right of renewal
          granted by this Paragraph 5(d), this Paragraph 5(d) shall be of no
          further force or effect and Tenant shall have no right to further
          renew or extend the term at the expiration of the renewal term.

          Within fifteen (15) business days after request thereof from Landlord,
     Tenant shall execute and deliver to Landlord those instruments which
     Landlord may request to evidence the renewal described in this Paragraph
     5(d). The rights of Tenant under this Paragraph 5(d) shall not be severed
     from the Lease or separately sold, assigned, or otherwise transferred, and
     shall expire on the expiration or earlier termination of the Lease.
     Notwithstanding the foregoing, the renewal option contemplated in this
     Paragraph 5(d) shall automatically terminate and become null and void and
     of no further force and effect upon the earlier to occur of (i) the
     expiration or termination of the Lease; (ii) the termination of the
     Tenant's right to possession of the Premises; or (iii) the failure of
     Tenant to timely or properly exercise the rights granted by this Paragraph
     5(d). The right contemplated by this Paragraph shall not survive the
     expiration or termination of this Lease, and shall not be available to any
     assignee, sublessee, or successor to Tenant's interests hereunder.

          (e) Market Rent. "Market Rent' means the amount of base rent, which
     may or may not include concessions, improvements, and other matters
     (exclusive of Operating Costs) which Landlord would receive by then renting
     similar space (including similar square footage) for premises in the
     project in which the Building is located. Within 45 days after Tenant
     exercised its right to renew the Term pursuant to Paragraph 5(d), Landlord
     shall give Tenant notice of Market Rent for the renewal term (the "Market
     Rent Notice"). If Tenant does not agree with Landlord's determination of
     Market Rent as set forth in the Market Rent Notice, Tenant shall so notify
     Landlord in writing within ten (10) days after Tenant's receipt of the
     Market Rent Notice ("Tenant's Notice"). Landlord and Tenant shall, for ten
     (10) days after Landlord's receipt of the Tenant's Notice, negotiate in
     good faith to come to an agreement as to Market Rent for the renewal term.
     If Landlord and Tenant are unable to agree upon Market Rent within said ten
     day period, then, notwithstanding the provisions of Paragraph 5(d), Tenant
     shall have the right to rescind the Renewal Notice of Exercise by written
     notice (the "Rescission Notice") to Landlord given not later than twenty
     (20) days after the date of the Tenant's Notice, it being understood and
     agreed that if the Rescission Notice is not given within such time period,
     Tenant shall be deemed to have waived its right to rescind the Renewal
     Notice of Exercise. In such case, to the extent that the Renewal Notice of
     Exercise was effectively exercised, Landlord and Tenant shall execute and
     deliver and amendment to the Lease which amendment shall be executed and
     delivered within ten (10) days following the determination of Market Rent.
     Tenant's failure to give the Tenant's Notice within the time period
     provided above shall be deemed an acceptance of Landlord's determination of
     Market Rent as set forth in the Market Rent Notice, and the term shall be
     deemed renewed pursuant to the Renewal Notice of Exercise.

     6. Reference to and Effect on the Lease.

<PAGE>

          (a) Upon the effectiveness of this Amendment, each reference in the
     Lease to "this Lease", "hereunder", "hereof", "herein" or words of like
     import referring to the Lease shall mean and be a reference to the Lease as
     amended hereby.

          (b) Except as specifically set forth above, the Lease remains in full
     force and effect and is hereby ratified and confirmed; provided, however,
     that the parties agree that the rights and obligations of each of them
     occurring prior to the Extension Commencement Date shall survive the
     execution and delivery of this Amendment.

          (c) Wherever there exists a conflict between this Amendment and the
     Lease, the provisions of this Amendment shall control.

     7. Governing Law. This Amendment shall be governed by and construed in
accordance with the laws of the State of Minnesota.

     8. Headings. Section headings in this Amendment are included herein for
convenience of reference only and shall not constitute a part of this Amendment
for any other purpose.

     9. Time of Essence. Time shall be of the essence as to each and every
provision of this amendment.

<PAGE>

     IN WITNESS WHEREOF, this Amendment has been executed as of the date first
written above.

TENANT:                                 LANDLORD:

ATS MEDICAL, INC.                       ST. PAUL PROPERTIES, INC.

By: /s/ Michael D. Dale                 By: /s/ Michael D. Elnicky
    ---------------------------------       ------------------------------------
Name: Michael D. Dale                   Name: Michael D. Elnicky
Title: President & CEO                  Title: Asset Manager

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}]]